Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 265


Clinical and immunological outcomes of a national paediatric cohort receiving combination antiretroviral therapy in Uganda.

Kiboneka A, Wangisi J, Nabiryo C, Tembe J, Kusemererwa S, Olupot-Olupot P, Joffres M, Anema A, Cooper CL, Montaner JS, Mills EJ.

AIDS. 2008 Nov 30;22(18):2493-9. doi: 10.1097/QAD.0b013e328318f148.


Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.


Characteristics of HIV-infected children seen in Western Kenya.

Nyandiko WM, Mwangi A, Ayaya SO, Nabakwe EC, Tenge CN, Gisore PM, Vreeman RC.

East Afr Med J. 2009 Aug;86(8):364-73.


Effect of nucleoside reverse transcriptase inhibitors on CD4 T-cell recovery in HIV-1-infected individuals receiving long-term fully suppressive combination antiretroviral therapy.

Byakwaga H, Zhou J, Petoumenos K, Law MG, Boyd MA, Emery S, Cooper DA, Mallon PW.

HIV Med. 2009 Mar;10(3):143-51. doi: 10.1111/j.1468-1293.2008.00663.x. Epub 2008 Dec 20.


CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR; Swiss HIV Cohort Study.

Clin Infect Dis. 2008 Oct 15;47(8):1093-101. doi: 10.1086/592113. Erratum in: Clin Infect Dis. 2009 May 15;48(10):1491.


Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.


Patients presenting with AIDS in the HAART era: a collaborative cohort analysis.

Mussini C, Manzardo C, Johnson M, Monforte Ad, Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi V, Lazzarin A, Miró JM, Sabin C; Late Presenter Investigators.

AIDS. 2008 Nov 30;22(18):2461-9. doi: 10.1097/QAD.0b013e328314b5f1.


Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.

Musoke PM, Mudiope P, Barlow-Mosha LN, Ajuna P, Bagenda D, Mubiru MM, Tylleskar T, Fowler MG.

BMC Pediatr. 2010 Aug 6;10:56. doi: 10.1186/1471-2431-10-56.


Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.


HIV-1 subtypes and response to combination antiretroviral therapy in Europe.

Bannister WP, Ruiz L, Loveday C, Vella S, Zilmer K, Kjaer J, Knysz B, Phillips AN, Mocroft A; EuroSIDA Study Group.

Antivir Ther. 2006;11(6):707-15.


Outcomes of HIV-infected orphaned and non-orphaned children on antiretroviral therapy in western Kenya.

Nyandiko WM, Ayaya S, Nabakwe E, Tenge C, Sidle JE, Yiannoutsos CT, Musick B, Wools-Kaloustian K, Tierney WM.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):418-25.


Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study.

Etard JF, Ndiaye I, Thierry-Mieg M, Guèye NF, Guèye PM, Lanièce I, Dieng AB, Diouf A, Laurent C, Mboup S, Sow PS, Delaporte E.

AIDS. 2006 May 12;20(8):1181-9.


Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group.

HIV Med. 2007 Mar;8(2):96-104.


CD4+ T-cell count increase in HIV-1-infected patients with suppressed viral load within 1 year after start of antiretroviral therapy.

Wolbers M, Battegay M, Hirschel B, Furrer H, Cavassini M, Hasse B, Vernazza PL, Bernasconi E, Kaufmann G, Bucher HC; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(6):889-97.


Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.

Selinger-Leneman H, Matheron S, Mahamat A, Moreau J, Costagliola D, Abgrall S; Clinical Epidemiology Group of the French Hospital Database on HIV (ANRS CO4).

J Acquir Immune Defic Syndr. 2008 Feb 1;47(2):206-11.


Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda.

Bakanda C, Birungi J, Mwesigwa R, Nachega JB, Chan K, Palmer A, Ford N, Mills EJ.

PLoS One. 2011 Apr 29;6(4):e19261. doi: 10.1371/journal.pone.0019261.


Clinical outcomes of HIV-infected patients with Kaposi's sarcoma receiving nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy in Uganda.

Asiimwe F, Moore D, Were W, Nakityo R, Campbell J, Barasa A, Mermin J, Kaharuza F.

HIV Med. 2012 Mar;13(3):166-71. doi: 10.1111/j.1468-1293.2011.00955.x. Epub 2011 Nov 24.


Clinical predictors of immune reconstitution following combination antiretroviral therapy in patients from the Australian HIV Observational Database.

Rajasuriar R, Gouillou M, Spelman T, Read T, Hoy J, Law M, Cameron PU, Petoumenos K, Lewin SR.

PLoS One. 2011;6(6):e20713. doi: 10.1371/journal.pone.0020713. Epub 2011 Jun 2.


Haematological changes after switching from stavudine to zidovudine in HIV-infected children receiving highly active antiretroviral therapy.

Aurpibul L, Puthanakit T, Sirisanthana T, Sirisanthana V.

HIV Med. 2008 May;9(5):317-21. doi: 10.1111/j.1468-1293.2008.00560.x. Epub 2008 Mar 10.


Results of a community-based antiretroviral treatment program for HIV-1 infection in Western Uganda.

Kipp W, Konde-Lule J, Saunders LD, Alibhai A, Houston S, Rubaale T, Senthilselvan A, Okech-Ojony J, Kiweewa F.

Curr HIV Res. 2010 Mar;8(2):179-85.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk